BioCentury
ARTICLE | Clinical News

FDA lifts partial hold on Aduro's candidates

November 21, 2016 11:59 PM UTC

Aduro Biotech Inc. (NASDAQ:ADRO) said FDA lifted a partial clinical hold on trials evaluating candidates developed using the company's Listeria monocytogenes-based immunotherapy construct (LADD) platform. The studies may resume enrollment. Patients in the trials had continued to receive treatment.

The agency placed the hold last month after a blood culture sample from a pancreatic cancer patient in Aduro’s Phase IIb ECLIPSE trial of LADD-based vaccine CRS-207 tested positive for Listeria several months after treatment (see BioCentury Extra, Oct. 24)...

BCIQ Company Profiles

Aduro Biotech Inc.

BCIQ Target Profiles

Mesothelin